{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:03:09Z","timestamp":1780380189944,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010377","name":"National Institute for Health and Care Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.parkreldis.2025.107889","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:02:57Z","timestamp":1748224977000},"page":"107889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["No one size fits all approach with apomorphine initiation"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7797-0756","authenticated-orcid":false,"given":"Christopher","family":"Kobylecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.B.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.107889_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson's disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.parkreldis.2025.107889_bib2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/mds.29066","article-title":"European academy of neurology\/movement disorder society-European section guideline on the treatment of Parkinson's disease: I. Invasive therapies","volume":"37","author":"Deuschl","year":"2022","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2025.107889_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2025.107889_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","article-title":"Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study","volume":"83","author":"Katzenschlager","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107889_bib5","series-title":"Parkinson's Disease in Adults","year":"2017"},{"issue":"9","key":"10.1016\/j.parkreldis.2025.107889_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107889_bib7","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"Auffret","year":"2023","journal-title":"J. Neural Transm."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107889_bib8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3233\/JPD-212735","article-title":"Barriers to accessing healthcare services for people with Parkinson's disease: a scoping review","volume":"11","author":"Zaman","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107889_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mdc3.12988","article-title":"Access and use of device-aided therapies for Parkinson's disease in Denmark","volume":"7","author":"Henriksen","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.107889_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3233\/JPD-202348","article-title":"Cost-effectiveness of device-aided therapies in Parkinson's disease: a structured review","volume":"11","author":"Smilowska","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107889_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mdc3.12965","article-title":"Management of advanced therapies in Parkinson's disease patients in times of humanitarian crisis: the COVID-19 experience","volume":"7","author":"Fasano","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107889_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2021.03.006","article-title":"Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany","volume":"85","author":"Richter","year":"2021","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107889_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00702-023-02686-7","article-title":"Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience","volume":"130","author":"Henriksen","year":"2023","journal-title":"J. Neural Transm."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.107889_bib14","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1111\/bcp.14737","article-title":"Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: a systematic review and meta-analysis of observational studies","volume":"87","author":"Ou","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2025.107889_bib15","article-title":"How to manage the initiation of apomorphine therapy without antiemetic pretreatment: a review of the literature","volume":"8","author":"Isaacson","year":"2023","journal-title":"Clin. Park Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.107889_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0000000000000082","article-title":"Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses","volume":"38","author":"Bhidayasiri","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.107889_bib17","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.parkreldis.2016.11.014","article-title":"Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy","volume":"33","author":"Bhidayasiri","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107889_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2025.107889_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/mds.26744","article-title":"Moving Parkinson care to the home","volume":"31","author":"Dorsey","year":"2016","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.107889_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","article-title":"Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients","volume":"264","author":"Sesar","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107889_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.parkreldis.2021.09.022","article-title":"Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: a prospective analysis of the Thai Apomorphine Registry","volume":"91","author":"Phokaewvarangkul","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107889_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X241310727","article-title":"Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: results from the phase 3, long-term, open-label United States InfusON study","author":"Isaacson","year":"2025","journal-title":"J. Parkinsons Dis."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107889_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00702-023-02609-6","article-title":"Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study","volume":"130","author":"Zagnoli","year":"2023","journal-title":"J. Neural Transm."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107889_bib24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-023-02710-w","article-title":"Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice","volume":"130","author":"Kobylecki","year":"2023","journal-title":"J. Neural Transm."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107889_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060525","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson's disease: a single-center, long-term follow-up study of the causes for discontinuation","volume":"11","author":"Henriksen","year":"2021","journal-title":"J. Personalized Med."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.107889_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/WNF.0000000000000361","article-title":"Long-term apomorphine infusion users versus short-term users: an international dual-center analysis of the reasons for discontinuing therapy","volume":"42","author":"Bhidayasiri","year":"2019","journal-title":"Clin. Neuropharmacol."},{"issue":"S1","key":"10.1016\/j.parkreldis.2025.107889_bib27","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.3233\/JPD-230224","article-title":"Parkinson\u2019s nurses are crucial for the management of Parkinson\u2019s disease: 2007-2024","volume":"14","author":"Thomas","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2025.107889_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1379459","article-title":"Integrating technology into a successful apomorphine delivery program in Thailand: a 10-year journey of achievements with a five-motto concept","volume":"15","author":"Phokaewvarangkul","year":"2024","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.107889_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3111\/13696998.2014.979937","article-title":"Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany","volume":"18","author":"Walter","year":"2015","journal-title":"J. Med. Econ."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.107889_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/s19102241","article-title":"The use of data from the Parkinson's KinetiGraph to identify potential candidates for device assisted therapies","volume":"19","author":"Khodakarami","year":"2019","journal-title":"Sensors (Basel)"},{"issue":"7","key":"10.1016\/j.parkreldis.2025.107889_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11070680","article-title":"Parkinson's disease: personalized pathway of care for device-aided therapies (DAT) and the role of continuous objective monitoring (COM) using wearable sensors","volume":"11","author":"Metta","year":"2021","journal-title":"J. Personalized Med."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:28:48Z","timestamp":1759624128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025006303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"alternative-id":["S1353802025006303"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107889","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No one size fits all approach with apomorphine initiation","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107889"}}